Targeting Dendritic Cells for Improved HIV-1 Vaccines

Author(s):  
Anna Smed-Sörensen ◽  
Karin Loré
Keyword(s):  
2013 ◽  
Vol 191 (1) ◽  
pp. 60-69 ◽  
Author(s):  
Kerrie J. Sandgren ◽  
Anna Smed-Sörensen ◽  
Mattias N. Forsell ◽  
Martina Soldemo ◽  
William C. Adams ◽  
...  

1998 ◽  
Vol 187 (10) ◽  
pp. 1623-1631 ◽  
Author(s):  
Jeanette C. Reece ◽  
Amanda J. Handley ◽  
E. John Anstee ◽  
Wayne A. Morrison ◽  
Suzanne M. Crowe ◽  
...  

Macrophage tropic HIV-1 is predominant during the initial viremia after person to person transmission of HIV-1 (Zhu, T., H. Mo, N. Wang, D.S. Nam, Y. Cao, R.A. Koup, and D.D. Ho. 1993. Science. 261:1179–1181.), and this selection may occur during virus entry and carriage to the lymphoid tissue. Human skin explants were used to model HIV-1 selection that may occur at the skin or mucosal surface. Macrophage tropic, but not T cell line tropic strains of HIV-1 applied to the abraded epidermis were recovered from the cells emigrating from the skin explants. Dermis and epidermis were separated by dispase digestion after virus exposure to determine the site of viral selection within the skin. Uptake and transmission to T cells of all HIV-1 isolates was found with the dermal emigrant cells, but only macrophage tropic virus was transferred by emigrants from the epidermis exposed to HIV-1, indicating selection only within the epidermis. CD3+, CD4+ T cells were found in both the dermal and epidermal emigrant cells. After cell sorting to exclude contaminating T cells, macrophage tropic HIV-1 was found in both the dermal emigrant dendritic cells and in dendritic cells sorted from the epidermal emigrants. These observations suggest that selective infection of the immature epidermal dendritic cells represents the cellular mechanism that limits the initial viremia to HIV-1 that can use the CCR5 coreceptor.


2018 ◽  
Vol 19 (1) ◽  
Author(s):  
Enrique Martin-Gayo ◽  
Michael B. Cole ◽  
Kellie E. Kolb ◽  
Zhengyu Ouyang ◽  
Jacqueline Cronin ◽  
...  

Virology ◽  
2007 ◽  
Vol 362 (1) ◽  
pp. 67-74 ◽  
Author(s):  
Aude Magérus-Chatinet ◽  
Huifeng Yu ◽  
Séverine Garcia ◽  
Elodie Ducloux ◽  
Benoit Terris ◽  
...  

2001 ◽  
Vol 75 (16) ◽  
pp. 7621-7628 ◽  
Author(s):  
Julianna Lisziewicz ◽  
Dmitry I. Gabrilovich ◽  
Georg Varga ◽  
Jianqing Xu ◽  
Philip D. Greenberg ◽  
...  

ABSTRACT A novel technology combining replication- and integration-defective human immunodeficiency virus type 1 (HIV-1) vectors with genetically modified dendritic cells was developed in order to induce T-cell immunity. We introduced the vector into dendritic cells as a plasmid DNA using polyethylenimine as the gene delivery system, thereby circumventing the problem of obtaining viral vector expression in the absence of integration. Genetically modified dendritic cells (GMDC) presented viral epitopes efficiently, secreted interleukin 12, and primed both CD4+ and CD8+ HIV-specific T cells capable of producing gamma interferon and exerting potent HIV-1-specific cytotoxicity in vitro. In nonhuman primates, subcutaneously injected GMDC migrated into the draining lymph node at an unprecedentedly high rate and expressed the plasmid DNA. The animals presented a vigorous HIV-specific effector cytotoxic-T-lymphocyte (CTL) response as early as 3 weeks after a single immunization, which later developed into a memory CTL response. Interestingly, antibodies did not accompany these CTL responses, indicating that GMDC can induce a pure Th1 type of immune response. Successful induction of a broad and long-lasting HIV-specific cellular immunity is expected to control virus replication in infected individuals.


Sign in / Sign up

Export Citation Format

Share Document